SPX3,831.39+6.06 0.16%
DIA309.71-1.14 -0.37%
IXIC11,322.24+194.39 1.75%

BRIEF-Seelos Therapeutics Announces Data Demonstrating Significant Downregulation Of Mrna And Reduction Of Alpha Synuclein In An In Vitro Gene Therapy Study

reuters.com · 06/09/2022 08:17
BRIEF-Seelos Therapeutics Announces Data Demonstrating Significant Downregulation Of Mrna And Reduction Of Alpha Synuclein In An In Vitro Gene Therapy Study

- Seelos Therapeutics Inc SEEL:

  • SEELOS THERAPEUTICS ANNOUNCES DATA DEMONSTRATING STATISTICALLY SIGNIFICANT DOWNREGULATION OF MRNA AND REDUCTION OF ALPHA SYNUCLEIN IN AN IN VITRO GENE THERAPY STUDY OF SLS-004 UTILIZING CRISPR-DCAS9 IN DEMENTIA WITH LEWY BODIES

  • SEELOS THERAPEUTICS - SINGLE DOSE OF SLS-004 PRODUCED 19% DOWNREGULATION OF MRNA AND ABOUT 40% REDUCTION OF ALPHA-SYNUCLEIN COMPARED TO CONTROL GROUP

  • SEELOS THERAPEUTICS INC- PLANS TO ADVANCE STUDY OF SLS-004 IN DLB IN ADDITIONAL PRECLINICAL STUDIES

Source text for Eikon: ID:nPn6KccY7a

Further company coverage: SEEL


((reuters.briefs@thomsonreuters.com;))